Table 3.
Disproportionality analysis for reports of sleep-related eating disorder (SRED).
| Active Ingredient | ROR | 95% CI | Number of Cases (%) |
|---|---|---|---|
| Zolpidem | 387.6 | 331.2–453.7 | 243 (35.9) |
| Sodium Oxybate | 204.2 | 172.4–241.8 | 185 (27.4) |
| Suvorexant | 67.3 | 38.0–119.2 | 12 (1.8) |
| Quetiapine | 53.3 | 43.0–66.1 | 97 (14.3) |
| Zopiclone | 43.6 | 24.6–77.2 | 12 (1.8) |
| Armodafinil | 40.8 | 16.9–98.4 | 5 (0.7) |
| Amfetamine; Dexamfetamine | 33.4 | 17.9–62.4 | 10 (1.5) |
| Temazepam | 32.7 | 13.6–78.9 | 5 (0.7) |
| Trazodone | 25.5 | 15.0–43.4 | 14 (2.1) |
| Modafinil | 24.0 | 7.7–74.8 | 3 (0.4) |
| Promethazine | 21.5 | 10.2–45.2 | 7 (1.0) |
| Tizanidine | 21.4 | 8.0–57.2 | 4 (0.6) |
| Lisdexamfetamine | 20.3 | 9.6–42.8 | 7 (1.0) |
| Ziprasidone | 16.9 | 7.6–37.7 | 6 (0.9) |
| Eszopiclone | 15.6 | 5.8–41.6 | 4 (0.6) |
| Aripiprazole | 15.4 | 10.2–23.1 | 24 (3.6) |
| Buspirone | 13.8 | 4.4–43.0 | 3 (0.4) |
| Pramipexole | 13.4 | 5.0–35.9 | 4 (0.6) |
| Topiramate | 13.4 | 7.2–25.0 | 10 (1.5) |
| Ethanol | 11.8 | 5.6–24.8 | 7 (1.0) |
| Vortioxetine | 11.6 | 4.3–30.9 | 4 (0.6) |
| Duloxetine | 11.3 | 7.1–18.1 | 18 (2.7) |
| Escitalopram | 10.3 | 5.4–20.0 | 9 (1.3) |
| Phenobarbital | 10.3 | 3.3–31.9 | 3 (0.4) |
| Lurasidone | 10.3 | 3.3–31.9 | 3 (0.4) |
| Phentermine | 10.2 | 4.3–24.7 | 5 (0.7) |
| Clonazepam | 9.9 | 5.1–19.2 | 9 (1.3) |
| Venlafaxine | 8.8 | 5.2–15.0 | 14 (2.1) |
| Hydrochlorothiazide | 7.4 | 3.1–17.8 | 5 (0.7) |
| Mirtazapine | 7.0 | 2.9–16.9 | 5 (0.7) |
| Olanzapine | 6.6 | 3.6–12.0 | 11 (1.6) |
| Alprazolam | 5.6 | 2.7–11.8 | 7 (1.0) |
| Fluoxetine | 5.0 | 2.6–9.6 | 9 (1.3) |
| Methylphenidate | 4.6 | 1.9–11.0 | 5 (0.7) |
| Sertraline | 4.3 | 2.2–8.7 | 8 (1.2) |
ROR: Reporting Odds Ratio; CI: Confidence Interval.